Envestnet Portfolio Solutions Inc. Invests $131,000 in Dynavax Technologies Co. (NASDAQ:DVAX)

Envestnet Portfolio Solutions Inc. bought a new stake in Dynavax Technologies Co. (NASDAQ:DVAX) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 10,269 shares of the biopharmaceutical company’s stock, valued at approximately $131,000.

A number of other large investors have also recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its holdings in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 2,034 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of Dynavax Technologies during the fourth quarter worth $71,000. Nisa Investment Advisors LLC grew its position in Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 1,076 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in Dynavax Technologies in the 3rd quarter valued at $89,000. 96.96% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on DVAX shares. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their price target for the company from $15.00 to $12.00 in a report on Tuesday, February 11th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Trading Down 0.3 %

Shares of Dynavax Technologies stock opened at $13.68 on Friday. The company has a 50-day moving average of $13.35 and a two-hundred day moving average of $12.49. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $14.63. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The stock has a market cap of $1.70 billion, a PE ratio of 76.00 and a beta of 1.23.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. The firm had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, research analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.